The Use of a Synthetic Cannabinoid in the Management of Treatment‐Resistant Nightmares in Posttraumatic Stress Disorder (PTSD)

Trauma
Written By Nick Martin, M.A.

Study

Synthetic cannabis to treat PTSD in 47 patients with continued nightmares despite traditional antidepressant treatment.

Results

72% of participants reported either cessation of nightmares or a significant reduction in nightmare intensity, along with subjective reports of increases in sleep time, the quality of sleep, and the reduction of daytime flashbacks and nightsweats.

Discussion

Potential benefits of cannabis to treat PTSD symptoms, especially sleep issues for individuals who have tried traditional pharmacological interventions.

Citation

Fraser G. A. (2009). The use of a synthetic cannabinoid in the management of treatment-resistant nightmares in posttraumatic stress disorder (PTSD). CNS neuroscience & therapeutics, 15(1), 84–88. doi:10.1111/j.1755-5949.2008.00071.x

Link To Study

Nick Martin, M.A.

Nick is a psychedelic facilitator and integration coach who holds a Masters in Counseling Psychology from Boston College.

Previous

The efficacy of nabilone, a synthetic cannabinoid, in the treatment of PTSD-associated nightmares: A preliminary randomized, double-blind, placebo-controlled cross-over design study
Next

3,4-methylenedioxymethamphetamine (MDMA)-assisted psychotherapy for post-traumatic stress disorder in military veterans, firefighters, and police officers